News Focus
News Focus
Followers 616
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: BioHedge post# 78602

Monday, 11/17/2014 12:12:50 PM

Monday, November 17, 2014 12:12:50 PM

Post# of 405212
The Brilacidin news is such a disruptive technology that most probably expect it to come out in a journal paper or major scientific convention. Not a company pr. This may be part of why the market hasn't reacted yet. They are waiting for definitive proof of what CTIX has. What we have in Brilacidin alone is quite amazing.

Potential investors need to read these last three press releases again.

http://cellceutix.com/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin/#sthash.LMpiSzG4.dpbs

http://cellceutix.com/cellceutixs-new-chief-operating-officer-dr-james-alexander-addresses-shareholders/#sthash.J9HKIef1.dpbs

http://cellceutix.com/patient-enrollment-in-cellceutix-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis-targeted-to-begin-in-december-2014/#sthash.5byO4MxQ.dpbs




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y